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Phantom studyBackground:Quantitative cardiovascularmagnetic resonance T1-mapping is increasingly used formyocardial tis-
sue characterization. However, the lack of standardization limits direct comparability between centers andwider
roll-out for clinical use or trials.
Purpose: To develop a quality assurance (QA) program assuring standardized T1 measurements for clinical use.
Methods: MR phantoms manufactured in 2013 were distributed, including ShMOLLI T1-mapping and reference
T1 and T2 protocols. We first studied the T1 and T2 dependency on temperature and phantom aging using phan-
tomdatasets from a single site over 4 years. Based on this, we developed amultiparametric QAmodel,whichwas
then applied to 78 scans from 28 other multi-national sites.
Results: T1 temperature sensitivity followed a second-order polynomial to baseline T1 values (R2 > 0.996). Some
phantoms showed aging effects, where T1 drifted up to 49% over 40months. The correlationmodel based on ref-
erence T1 and T2, developed on 1004 dedicated phantom scans, predicted ShMOLLI-T1 with high consistency
(coefficient of variation 1.54%), andwas robust to temperature variations and phantomaging. Using the 95% con-
fidence interval of the correlationmodel residuals as the tolerance range,we analyzed390 ShMOLLI T1-maps and
confirmed accurate sequence deployment in 90%(70/78) of QA scans across 28multiple centers, and categorized
the rest with specific remedial actions.
Conclusions: The proposed phantomQA for T1-mapping can assure correctmethod implementation and protocol
adherence, and is robust to temperature variation and phantom aging. This QA program circumvents the need of
frequent phantom replacements, and can be readily deployed in multicenter trials.
© 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
CMR parametric mapping permits the quantification and spatial vi-
sualization of changes in myocardial composition based on changes in
T1, T2 relaxation times, and extracellular volume (ECV) [1]. Native T1-
mapping has been shown to have narrow normal ranges within the
same method, and sensitivity to a wide range of myocardial diseases
[2,3]. Its advantages include relatively simple single breath-hold acqui-
sitions, excellent reproducibility, and avoidance of gadolinium-based
contrast agents.
However, T1 values depend on the protocol parameters, acquisition
and reconstruction methods [4], currently requiring cumbersome es-
tablishment of within-center norms [1,5]. Native T1-mapping can dif-
ferentiate disease from healthy tissue in single-site studies at a fixed
field strength, and demonstrated reproducibility inmulti-center studies
under a uniform imaging set-up, but the lack of standardization limits
direct comparability between centers and wider roll-out for clinical
use. For clinical sites attempting to implement T1 mapping, it is often
unclear how to install and validate the methods correctly before using
them for clinical diagnosis, or for assessing novel therapeutics in
multi-center trials. Despite SCMR consensus recommendations [1],
there has been no working solution to-date for standardization – not
even for a single T1-mapping technique on a single vendor platform.
The use of local normal ranges and z-scores to adjust for differences
have been proposed [1], but are suboptimal, as small sample size (e.g.
10–20) healthy volunteers can be prone to sampling errors [1,5]; out-
liers or biases could directly affect a center's ability to detect abnormal
findings to diagnose disease. While these effects decrease with larger
sample sizes, re-acquiring such data frequently just to monitor stability
after each method or scanner upgrade becomes prohibitively cumber-
some and expensive.
Validation and quality assurance (QA) of single-method deploy-
ment could be a first step to standardize T1-mapping techniques, in-
creasing the confidence of individual centers in the set-up of CMR
mapping for clinical use. The large, international multicenter Hyper-
trophic Cardiomyopathy Registry (HCMR) study [6] adopted a single
T1-mapping method (Shortened Modified Look-Locker Inversion2
Recovery, ShMOLLI [7]) to maximize comparability of the datasets
to power for outcomes. This study setup provided an opportunity
to collect the required phantom data to develop a QA program for
standardizing T1-mapping between centers, using an original
multiparametric modelling approach. The derived QA model can re-
liably detect deviations from correct method implementation and
protocol adherence, despite changes in phantom properties, includ-
ing temperature variations [8,9] and aging effects, unlike most phan-
tom solutions currently available [9,10].
2. Materials and methods
2.1. Study design
In 2013, a batch of 50 original dedicated QA phantom devices was designed for
the prototype ShMOLLI T1-mapping method [7]. The manufacture details are pro-
vided in Supplemental Section S1. The external appearance and arrangement of the
phantom compartments are shown in Fig. 1a, b, and the achieved T1 and T2 combina-
tions in Table 1.
The QA program aimed to assure the detection and compensation of potential
differences in T1-mapping sequence properties between sites to track T1 measure-
ment stability [6]. Centers operating Siemens MR scanners and performing measure-
ments free of charge (N = 28) were provided a consistent protocol developed at
Oxford core lab, adapted for various Siemens software platforms. The sites were pro-
vided with imaging manuals and HCMR QA protocols to perform repeated ShMOLLI-
T1 acquisitions, an inversion recovery spin echo (IR-SE) acquisition and a multi-echo
SE acquisition for reference T1 and T2 maps (protocol specified in Supplemental
Section S2). The multi-center dataset collected from the HCMR sites served to moni-
tor site-specific changes of the T1-mapping technique properties. Meanwhile phan-
toms were repeatedly scanned at Oxford core lab on a MAGNETOM Avanto (1.5 T)
and a MAGNETOM Trio Tim (3 T) scanners (Siemens Healthcare, Erlangen,
Germany). This high-volume dataset served to investigate temperature and age de-
pendencies as well as to establish the QA protocol.
The phantom scans were uploaded by individual HCMR sites to Boston core lab
and then sent to Oxford core lab for data analysis between July 2014 and December
2017, when the first phase of the HCMR study was completed [6]. 28 HCMR sites
using Siemens scanners acquired and sent 78 scans (a complete list of HCMR sites
providing the phantom scans is given in Supplemental Table S1). Meanwhile, locally
at Oxford core lab, we acquired 441 phantom studies between October 2013 and June
2017. Each study scanned one to three phantoms, which provided a total of 1004
phantom scans for analysis.
All reference T1 and T2 maps were calculated offline by a C++ library [11]. We
analyzed the T1 and T2 using the robust mean values from the circular (15 mm
Fig. 1. HCMR QA phantom. (a) Phantom external appearance. (b) Phantom compartment arrangement. (c) An example of T1 map in QA post-processing. Black dashed lines indicate the
automatically detected ROIs. The two phantoms on either side are not part of QA; their use is recommended to assure adequate coil loading.
Q. Zhang, K. Werys, I.A. Popescu et al. International Journal of Cardiology xxx (xxxx) xxxdiameter) regions of interest within each of the phantom compartments (Fig. 1c),
which were placed automatically by a machine learning algorithm [12]. Altogether,
from each set of phantom scans, we obtained 9 sets of reference T1 (T1ref) and T2
measurements paired with 5 repeats of corresponding ShMOLLI-T1 (T1sh) for each
compartment.2.2. T1 and T2 dependencies on temperature and phantom aging
To investigate the T1 and T2 dependency on temperature, we scanned phantoms at
temperatures ranging from 16 °C to 28 °C. To analyze phantom property drifts over
time, four selectedphantomswere scanned approximately every twoweeks between Feb-
ruary 2014 and June2017,with an average of 148 studies acquired per phantomover a 40-
month period. We evaluated time trends in T1ref and T2, corrected to room temperature
(21 °C) using the established temperature dependencies.2.3. T1 prediction model and T1-mapping quality assurance
We postulated that the measured cardiac ShMOLLI-T1 has a predictable dependency
on T1ref and T2 in phantoms. Using the dataset acquired locally at Oxford core lab, we
established a single empirical equation exploiting the inherent relationship, T1sh= Func-
tion (T1ref, T2), for all T1 and T2 combinations. The residual of fitting was calculated to es-
tablish the range of agreement for the QA program. The equationwas then used to predict
the expected ShMOLLI-T1 fromT1ref and T2, and compare itwith observed ShMOLLI-T1 in
the same QA scan to check the agreement. Phantom scans with ShMOLLI-T1 of all com-
partments within the agreement range (the 95% confidence interval (CI) of the residual
of fitting; see results section) would indicate an accurate ShMOLLI sequence deployment
and, therefore, QA passed. If any ShMOLLI-T1 fell outside the agreement range, the pattern
of discrepancy and the scanning parameters were then further inspected, to identify po-
tential sources of error. These may include artefacts, reconstruction error or protocol
error, and are given a conditional pass with specific recommendations for remedial ac-
tions. Failing to identify and rectify errors would suggest that the ShMOLLI sequence
was deployed incorrectly, and, therefore, QA failed. The capacity of this method was vali-
dated on the multi-center HCMR phantom dataset for Siemens scanners, with proof-of-
principle translation demonstrated on the Philips platform.Table 1
Phantom chemical composition and T1/T2 relaxation times measured at room temperature wi
measured at 1.5 T and 3 T. The T2 are average values of five randomly selected phantoms at 1
Phantom compartment and formulation ShMOLLI T1 [ms] (mea
1.5 T (21.3 ± 0.4 °C)
A 0.5% Agar, 0.33% Carrageenan, 0.113 mM NiCl2 2529.5 ± 14.0
B 0.5% Agar, 0.626 mM NiCl2 1396.2 ± 5.9
C Undoped 18 MΩ deionized H2O 3251.5 ± 12.5
D 1.9% Agar, 1.2 mM NiCl2 859.1 ± 2.9
E 2% Agar, 0.77 mM NiCl2 1109.7 ± 12.5
F 2% Agar, 0.524 mM NiCl2 1397.8 ± 4.7
G 1.5% Agar, 0.1% Carrageenan, 4.5 mM NiCl2 323.1 ± 0.66
H 3% Agar, 0.457 mM NiCl2 1428.8 ± 3.9
I 1.8% Agar, 2 mM NiCl2 610.2 ± 1.3
3
3. Results
3.1. T1 baseline values and temperature dependency
At the time of manufacture, all 9 compartments of the 50 phantoms
made as a batch had consistent ShMOLLI-T1 values with coefficient of
variation within 0.85%, all measured at room temperature of ~21 °C
(Table 1). In contrast to in-vivo myocardial T1 values [7], ShMOLLI-T1
values of all phantom compartments were lower at 3 T than at 1.5 T
by 0.5–6.8% (all p < 0.001). Phantom T2 were typically lower at 3 T by
2.1–3.7% (all p < 0.001), with the exception of compartment #E
where T2 was 1.6% higher at 3 T than at 1.5 T (p < 0.001). In compart-
ments #C and #H, the T2 difference did not reach statistical significance
(Table 1).
In subsequent experiments, T1ref showed clear linear dependency
on temperature at both 1.5 T and 3 T (Fig. 2a). The variation of predicted
T1 changes with temperature was 2.6% ± 1.5% at 1.5 T and 2.6% ± 1.2%
at 3 T for all compartments, relative to the baseline T1 in Table 1. The
temperature sensitivity increased with baseline T1, following closely a
second-order polynomial (R2 > 0.996; Fig. 2b).3.2. Impact of phantom aging on T1
A wide range of aging effects were observed on the reference T1
measurements, with the largest seen in compartment #B in three of
the four phantoms scanned repeatedly at Oxford core lab (Fig. 3).
These phantoms appear to have undergone a transition, whereby the
baseline T1 values had increased by ~50%. This may be due to various
factors during the manufacture, particularly the amount of air withinthin one month of manufacture. ShMOLLI T1 are average values of a batch of 50 phantoms
.5 T and another five at 3 T scanned in an additional single measurement.
n ± SD, N = 50) Spin-echo T2 [ms] (mean ± SD, N = 5)
3 T (21.0 ± 0.5 °C) 1.5 T (21.0 °C) 3 T (21.0 °C)
2461.0 ± 7.8 275.8 ± 2.1 265.9 ± 4.8
1329.4 ± 2.2 266.2 ± 4.6 259.0 ± 2.2
3234.9 ± 27.8 2373.4 ± 184.3 2383.1 ± 153.9
804.71 ± 0.74 72.2 ± 0.7 71.4 ± 0.4
1051.3 ± 1.9 69.6 ± 1.2 70.7 ± 0.8
1328.0 ± 2.2 80.2 ± 1.4 78.4 ± 2.8
307.5 ± 0.6 72.4 ± 0.7 68.5 ± 1.1
1368.1 ± 3.4 56.9 ± 0.4 56.5 ± 2.6
574.4 ± 0.5 74.0 ± 0.7 72.5 ± 1.5
Fig. 2. Temperature sensitivity of reference T1 in the Oxford core lab dataset at 1.5 T and 3 T. (a) T1 temperature dependency. Temperature sensitivity coefficients (ΔT1/Δt, ms/°C) are
provided to the right of the graph, prefixed with the compartment ID. Regression lines are omitted for clarity. (b) T1 temperature sensitivity coefficients (Y-axis) follow a second-order
polynomial to baseline T1 values (X-axis).
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teristics are provided in supplemental Fig. S4 and S5.
3.3. T1 predictionmodel robust to temperature variation and phantomaging
Consistent with prior work, ShMOLLI-T1 generally followed a linear
relationshipwith T1ref, with visibly larger underestimation in compart-
ments with shorter T2 (Fig. 4a, red arrows). To establish a model inde-
pendent of phantom age and temperature, we exploited the inherent
relationships between ShMOLLI-T1 and T1ref and T2, based on the
1004 dedicated phantom datasets. We accounted for the linear depen-
dency of ShMOLLI-T1 on T1ref, and an exponential dependency on T2
(coefficients calculated for 1.5 T and 3 T, respectively; full data samples
in Supplemental Fig. S6). While this model significantly reduced the re-
sidual differences between ShMOLLI-T1 and reference T1methods from
7.24% to 1.64% (p < 0.001), there was a remaining small trend visible in
the fit residuals. This was rectified with a third-order polynomial
correction. The final multivariate correlation model predicting the
ShMOLLI-T1 (cT1sh) from reference measurements were thus establi-
shed; see derived equations in Suplemental S3. The model predicted
cT1sh which agreed with real T1sh with high accuracy (R2 > 0.99,
Fig. 4b), despite the temperature variation and phantom aging effects
described above. Analysis of the residual errors of the ShMOLLI predic-
tion model allowed the establishment of the 95% confidence interval
CI = ±3.12%, and the 99.7% confidence interval CI = ±5.32%, robust
to temperature and aging confounders. The 95% CI was used as the tol-
erance range for the QA (full data samples in Supplemental Fig. S7).4
3.4. Clinical application: T1-mapping quality assurance
We received 94 phantom scans: 78 from 28 Siemens sites, 15 from 6
Philips sites, and 1 from a General Electric (GE) site (complete list of
sites in Supplemental Table S1). The vendor and scan distribution
reflected the resources available and local feasibility during this study,
which precluded fair head-to-head inter-vendor comparisons. We
were able to perform QA and present the findings in 78 scans (390
ShMOLLI-T1 maps) from the 28 Siemens sites (Table 2 and Fig. 5). We
exemplified the need for further work for inter-vendor application of
the QA model (Fig. 5f), subject to sufficient datasets acquired on those
MR systems.3.5. QA passed
QAwas passed if the dataset from a session contained at least one
accurate ShMOLLI-T1 acquisition for all 9 compartments. 34 scans
from 15 sites gave ShMOLLI-T1 values within the prescribed 95% CI
range of the expected ShMOLLI-T1, confirming accurate ShMOLLI de-
ployment (Fig. 5a). Three scans from 3 sites showed departure of
ShMOLLI-T1 values in individual phantom compartments, with the
rest being within the agreement range. We identified the sources
of these outliers as imaging artefacts in the reference T1-maps
(Fig. 5b). These 3 scans were considered to have passed the QA, as
the source of discrepancies was clearly outside the cardiac T1-
mapping technology, and the ShMOLLI-T1 values of the rest of the
compartments were within the agreement range.
Fig. 3. The varied appearance of age-related drifts in reference T1 (T1ref) in individual phantom compartments observed over a period of 40months. All T1ref values are corrected to room
temperature. Colors represent the four phantoms investigated.
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A further 26 scans from 16 sites provided at least one accurate
ShMOLLI acquisition but with a characteristic pattern of greater under-
estimation of ShMOLLI-T1 values in longer T1 compartments in other
acquisitions of the scan (Fig. 5c), suggesting incomplete recovery of
magnetization. This was likely caused by inadequate waiting time
after the previous image acquisition, frequency adjustment, or shim-
ming adjustment. We reproduced this T1 underestimation at Oxford
core lab with dedicated experiments, and studied the impact of incom-
plete magnetization recovery on the measured T1. The experimental
details are provided in Supplemental Section S4. This error may be rec-
tified by reminding the operators to wait at least 10 s in between T1-
map acquisitions.
3.7. Common error 2: failed in-line reconstruction of T1-mapping
We detected incorrect in-line ShMOLLI-T1 reconstruction in 7 addi-
tional scans from 5 sites (Fig. 5d, gray circles). We were able to recon-
struct and salvage T1-maps offline using raw T1-weighted images, and
restored the accurate T1 values (Fig. 5d, blue points). This indicated cor-
rect T1-weighted image acquisition but inaccurate inline reconstruction
on the MR system. Therefore, these sites passed QA conditionally on
offline reconstruction, but required redeployment of the T1 sequence.
3.8. QA failed
Six scans did not provide T1measurements fallingwhollywithin the
prescribed tolerance limit, and therefore did not pass QA (Fig. 5e). A
further 2 scans from 2 sites contained no reference T1 or T2 acquisi-
tions, and thus the QA was not performed. Similarly, incompatible5
measurement protocols prevented a convincing inter-vendor valida-
tion, with one example shown as a proof of principle (Fig. 5f).4. Discussion
In this work, we have established a novel approach for quality assur-
ance (QA) that is independent of the actual physical properties of the
phantoms, bypassing the exhibited phantom sensitivities to tempera-
ture variations and aging. We have demonstrated how to use this QA
to verify correct implementation of T1-mapping methods to within a
prescribed tolerance range across multiple scanners and magnetic
field settings; signature patterns of departure also identified common
errors for actionable remediations.4.1. Inter-method and inter-vendor applications
We have illustrated how to achieve this phantom QA solution using
a single T1-mappingmethod, but the solution can be deployed to other
mapping techniques. The HCMR Consortium had chosen a single T1-
mapping method (ShMOLLI [7]) to maximize comparability of the
datasets to power for outcomes. The ShMOLLI T1-mapping sequence
possesses three characteristics which made this work possible within
5 years: (1) method stability and full accountability of its quantitative
characteristics, such that it was feasible to compare it on a wide range
of platforms within a single vendor setting; (2) heart-rate indepen-
dence, alleviating the need to vary heart rate as part of the QA process;
(3) ShMOLLI is a single universal technique suitable for measuring a
wide range of T1 values (whether short or long), thus obviating the
need for developing separate QA models, each for a specific MOLLI
sub-variant for short or long T1s.
Fig. 4. ShMOLLI T1 (T1sh) against reference T1 (T1ref) in the Oxford core lab dataset before T2 correction (a) and after T2 correction (b) at 1.5 T and 3 T. (a) The visible deviations (red
arrows) were driven predominantly by T2 effects. (b) The multivariate correlation model including T2 effects predicts T1sh with high accuracy (R2 > 0.99). (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of this article.)
Table 2
QA results of 78 Siemens scans from 28 sites with proposed outcomes and actions.
QA Results Description No. scans
(sites)
Action recommended
1. Passed All T1 maps in the scan provided ShMOLLI-T1 (T1sh) values within the agreement range with




No further action required
Disagreement between T1sh and cT1sh in one or more individual compartments; the rest were in
the agreement range. The source of error can be identified as image artefacts not linked to cardiac





2. Warnings Underestimated T1sh in individual acquisitions. At least one acquisition is within the agreement
range. Incomplete recovery of longitudinal magnetization in individual acquisitions (Fig. 5c).
26 scans
(16 sites)
QA passed, with warning of possible
protocol adherence problems
3. Conditional T1sh values outside the agreement range; Source of disagreement caused by T1 map fitting
without ShMOLLI conditional fitting reconstruction, but accurate T1sh values were successfully
restored offline (Fig. 5d).
7 scans
(5 sites)
QA conditional on offline reconstruction.
Require re-deployment of T1 sequence
4. Failed T1sh values outside the agreement range; unable to identify source of error. Unable to restore
accurate T1sh values offline (Fig. 5e).
6 scans
(3 sites)
QA not passed. Technical investigation
required
QA could not be performed due to missing reference T1 or T2 sequences in the scan. 2 scans
(2 sites)
Incomplete scan. Check protocols and
repeat QA
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methods across vendor platforms, subject to the exact application of
the specified protocols. The provided scanning protocol (Supplemental
Section S2) and presented QA formula can be readily tested on other
vendorMR systems as published, subject to the availability of vendor re-
search personnel and support of technical development sites. Even
though our experience indicates that this is far from trivial, by setting
clear and achievable QA goals, the proposed QA program offers for the
first time a practical way towards a fully compatible inter-vendor T1
methodology.
4.2. Study limitations and future work
The proposed QA program was demonstrated on a single vendor
platform. Although the general approach can be applied across vendors,
the investigators' experience indicates that translation to other vendors
and methods will require significant further technical investment,
to address the large intervendor differences between documented sim-
ilar methods [10]. The authors are open to collaborative requests to
employ the proposed QA to improve the T1-mapping consistency in
multi-vendor setting. In future, the described QA should be either im-
plemented directly on the scanner or be provided as a prompt external
service, so that end-users can assuremethod stabilitywith the same fre-
quency as the usual scanner QA. This QA is designed to test correct tech-
nical deployment ofmethods; operator compliancewith the acquisition
protocols and standardization of image processing [13] are required to
minimize introduction of errors.
5. Conclusions
We presented the development of a practical MR phantom QA pro-
gram for accurate and comparable T1 measurements for use in a large
multi-center setting. The QAmodel is robust to phantom aging and am-
bient temperature variations, circumventing the need for manual tem-
perature corrections and frequent phantom replacements. This
provides an immediate and economical solution to verify correct T1-
mapping method implementation, and identify common errors for re-
mediation. The proposed QA program paves the way to widespread
adoption of T1-mapping into routine clinical practice.
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